[Immunotherapy with decaris in the early stages of breast cancer].

A randomized clinical study of adjuvant immunotherapy with decaris was carried out in patients with early breast cancer. 92 patients with stages I and IIA tumors (T1,2N0M0) received 300 mg decaris weekly (150 mg for 2 successive days) 2 weeks after radical mastectomy (Patey) used as a sole preventive therapy. The short (1 month) (group I), the medium (3 months) (group 2) and the long-term intermittent (three 3 month courses during 15 months) (group 3) modalities were compared. The prolonged intermittent course of decaris administration proved superior since it assured improvement in immunity and longer relapse-free survival, and lacked apparent toxicity. Five-year survival in all decaris treated patients was 93.8%, while five-year relapse-free course in group 3 was registered in 96.9%.